Literature DB >> 7121252

Fluoride in serum and bone during treatment of osteoporosis with sodium fluoride, calcium and vitamin D.

R G van Kesteren, S A Duursma, W J Visser, J van der Sluys Veer, O Backer Dirks.   

Abstract

Thirteen patients with primary osteoporosis were treated for two years with sodium fluoride (NaF), calcium and dihydrotachysterol (group A). The dose of NaF was modified according to the serum fluoride concentration, which was kept as constant as possible between 0.20 and 0.25 microgram/ml. In patients with bone fluoride content greater than or equal to 0.20% a significant increase in the volumetric density and in the surface percentage covered with osteoid and with osteoblasts was observed. A second group of 7 patients with primary osteoporosis was also treated for 2 years with calcium and dihydrotachysterol, but without fluoride (group B). In these patients no significant change in the volumetric density or in the surface percentage covered with osteoid or osteoblasts was found. Patients in group A with a bone fluoride content less than 0.20% could not be distinguished from the patients in group B. Based on the available data an advice was given for the dosage of NaF in patients with osteoporosis. Regular assessment of the serum fluoride concentration remains advisable.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7121252     DOI: 10.1016/0221-8747(82)90006-6

Source DB:  PubMed          Journal:  Metab Bone Dis Relat Res        ISSN: 0221-8747


  7 in total

1.  Fluoride treatment in osteoporosis.

Authors:  P Pitt; H Berry
Journal:  Postgrad Med J       Date:  1991-04       Impact factor: 2.401

2.  Inhibitory effect of fluoride on the secretion of insulin.

Authors:  A Rigalli; J C Ballina; E Roveri; R C Puche
Journal:  Calcif Tissue Int       Date:  1990-05       Impact factor: 4.333

3.  Effects of sodium fluoride, vitamin D, and calcium on cortical bone remodeling in osteoporotic patients.

Authors:  J Kragstrup; Z Shijie; L Mosekilde; F Melsen
Journal:  Calcif Tissue Int       Date:  1989-12       Impact factor: 4.333

4.  Pharmacokinetic profile of a new fluoride preparation: sustained-release monofluorophosphate.

Authors:  H Resch; C Libanati; J Talbot; M Tabuenca; S Farley; P Bettica; W Tritthart; D Baylink
Journal:  Calcif Tissue Int       Date:  1994-01       Impact factor: 4.333

Review 5.  Fluoride therapy for osteoporosis: a review of dose response, duration of treatment, and skeletal sites of action.

Authors:  B A Dure-Smith; M E Kraenzlin; S M Farley; C R Libanati; E E Schulz; D J Baylink
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

6.  Relationship between bone fluoride content and histological evidence of calcification defects in osteoporotic women treated long term with sodium fluoride.

Authors:  G Boivin; J Duriez; M C Chapuy; B Flautre; P Hardouin; P J Meunier
Journal:  Osteoporos Int       Date:  1993-07       Impact factor: 4.507

7.  Visible colorimetric fluoride and hydroxide sensing by asymmetric tris-urea receptors: combined experimental and theoretical studies.

Authors:  Ruyu Wang; Xi Shu; Yu Fan; Shoujian Li; Yongdong Jin; Chao Huang
Journal:  RSC Adv       Date:  2018-11-26       Impact factor: 4.036

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.